Home›Trial›NCT03911505
🔬NCT03911505Phase 3ACTIVE NOT RECRUITING

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

Study Summary

This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years

Conditions
Pompe Disease (Late-onset)
Interventions / Drugs
Cipaglucosidase AlfaMiglustat
View on ClinicalTrials.gov ↗
Sponsor
FOLD
Amicus Therapeutics
Rare Disease
C62/100
Study Details
Enrollment21 participants
Primary Completion—
Lead SponsorAmicus Therapeutics
Data Retrieved2026-04-11 04:14:12.640530+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.